Kodiak Sciences Inc Common Stock (KOD)
Stock · NASDAQ · Health Care
$85.72as of 10/16/2026
Price chart
Active signals
KOD Signal Track Record
How signals performed across all stocks →What KOD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +13.3% | 65% | September 24, 2026 |
| Bollinger Band Breakout | 29 | +11.5% | 59% | September 28, 2026 |
| Bollinger Band Breakdown | 18 | +13.1% | 56% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -13.9% | 38% | September 14, 2026 |
| Any 20-session window (baseline) | +3.4% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical stu…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 141
- Website
- kodiak.com/
Fundamentals
- 1-day range
- $79.06$88.5
- Market cap
- $2.84B
- P/E (trailing)
- —
- P/E (forward)
- -25.65
- EPS (trailing)
- $-4.19
- Dividend yield
- —
- Beta
- 1.95
- Avg. volume
- 1.65M
Forecasts
6 analyst ratings
Kodiak Sciences Inc Common Stock Competitors
Chosen by industry and closest market cap.
- KODKodiak Sciences Inc Common Stock$85.75▼ 2.69%Market cap $2.84BP/E —$10.94$104
- BEAMBeam Therapeutics Inc. Common Stock$23.47▼ 5.10%Market cap $2.81BP/E —$20.23$38.26
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KOD Kodiak Sciences Inc Common Stock | $2.84B | — | $85.75 | ▼ 2.69% | $10.94$104 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.81B | — | $23.47 | ▼ 5.10% | $20.23$38.26 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - SlideshowSeekingAlpha · 10/10/2026
- Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data UpdateYahoo · 10/8/2026
- Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial NewsYahoo · 10/8/2026
- Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026Yahoo · 10/7/2026
- Top 3 Health Care Stocks That May Collapse In Q4Benzinga · 10/5/2026
- PepsiCo, Delta Lead Upcoming Earnings Slate; Fed Minutes In FocusSeekingAlpha · 10/3/2026
- Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III StudyYahoo · 10/2/2026
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingYahoo · 10/2/2026
- Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drugbenzinga · 9/28/2026
Insider Activity
Insider Actions →- Victor Perlroth · September 25, 2026 · Option Exercise314.7K @ $3.95
- Victor Perlroth · September 25, 2026 · Option Exercise365.8K @ $2.49
- Victor Perlroth · September 25, 2026 · Option Exercise600.0K @ $5.38
- John A. Borgeson · July 15, 2026 · Grant66.5K
- Victor Perlroth · July 15, 2026 · Grant100.0K
- Bassil I. Dahiyat · June 30, 2026 · Grant17.7K
- Bancroft Charles A · June 30, 2026 · Grant17.7K
- Richard S. Levy · June 30, 2026 · Grant17.7K
- Yang Taiyin · June 30, 2026 · Grant17.7K
- Robert Profusek · June 30, 2026 · Grant17.7K
- BAKER BROS. ADVISORS LP · June 30, 2026 · Grant17.7K
- John A. Borgeson · June 4, 2026 · Option Exercise30.0K @ $1.04
- John A. Borgeson · June 4, 2026 · Sale4.1K @ $34.67
- John A. Borgeson · June 4, 2026 · Sale25.9K @ $34.01
- John A. Borgeson · April 15, 2026 · Option Exercise28.6K @ $1.04
Institutional Ownership
March 31, 2026
- Total shares held
- 58.17M
- Total value held
- $2.10B
- Institutional holders
- 185
- Unknown19.92M
- Unknown3.94M
- Unknown2.25M
- Unknown2.04M
- Unknown1.82M
- Unknown1.74M
- Unknown1.72M
- Unknown1.49M
- Unknown1.45M
- Unknown1.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data
HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data. HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.